Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




May
05
Today In Oncology
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
CLL Linked to Increased Skin Cancer Risk and Mortality
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo